FDA Patient Materials

Patient and prescriber education on biosimilars is critical to drive increased use of these life-saving therapies — bringing more treatment options and significant savings to patients and the U.S. health care system. The U.S. Food and Drug Administration (FDA), after direct feedback from patient advocacy groups and key stakeholders on the need for greater biosimilar education, developed new Patient Materials to increase awareness and understanding of the benefits of biosimilars.